文献速递心脑血管急症消化、代谢与肾脏急症

当代绝经激素治疗与血栓性疾病:全国性巢式病例对照研究

Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study.
PubMed 文献 · BMJ · 2026-09-23
一句话结论口服绝经激素治疗增加静脉血栓栓塞风险,经皮治疗未增加血栓风险。

该研究为丹麦全国性巢式病例对照研究,纳入50-69岁无相关病史女性,评估当前使用绝经激素治疗与静脉血栓栓塞、缺血性卒中和心肌梗死的关联。结果发现口服雌激素(单用或联合孕激素)增加静脉血栓栓塞(HR 1.6)、缺血性卒中(HR 1.3)和心肌梗死(HR 1.2)风险,绝对风险增加分别为每年0.09%、0.06%、0.03%,对应NNT分别为1055、1642、3846。口服雌二醇>1 mg/d使用超过1年与缺血性卒中和心肌梗死风险增加相关,且风险随疗程延长而增加。经皮治疗除经皮联合周期性治疗增加心肌梗死风险(HR 2.1)外,未增加血栓风险。

要点

  • 口服绝经激素治疗(单用或联合孕激素)增加静脉血栓栓塞风险(HR 1.6, 95%CI 1.5-1.8),绝对风险增加0.09%/年,NNT=1055。
  • 口服雌二醇>1 mg/d使用超过1年增加缺血性卒中(HR 1.8, 95%CI 1.4-2.2)和心肌梗死(HR 1.8, 95%CI 1.4-2.4)风险,使用>5年风险更高。
  • 经皮治疗未增加血栓风险,但经皮联合周期性治疗增加心肌梗死风险(HR 2.1, 95%CI 1.1-4.1)。
  • 口服雌激素增加缺血性卒中风险(HR 1.3, 95%CI 1.2-1.4)和心肌梗死风险(HR 1.2, 95%CI 1.1-1.3)。

适用人群与场景

  • 50-69岁居住在丹麦的女性,2003-2021年间,无静脉血栓、动脉血栓、癌症、肝病、血栓形成倾向、卵巢切除术、不孕治疗、子宫内膜异位症或多内分泌代谢性卵巢综合征(PMOS,旧称多囊卵巢综合征)病史。

诊断标准与关键阈值

  • 当前使用口服雌激素治疗(单用或联合孕激素)定义为暴露;当前未使用任何激素治疗为参照。
  • 口服雌二醇剂量>1 mg/天且使用超过1年定义为高剂量长期使用。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 当前口服雌激素治疗(单用或联合孕激素)与静脉血栓栓塞风险增加相关(HR 1.6, 95%CI 1.5-1.8),绝对风险增加0.09%/年(95%CI 0.08-0.13%),NNT=1055(95%CI 791-1266)。
  • 当前口服雌激素治疗与缺血性卒中风险增加相关(HR 1.3, 95%CI 1.2-1.4),绝对风险增加0.06%/年(95%CI 0.04-0.08%),NNT=1642(95%CI 1232-2463)。
  • 当前口服雌激素治疗与心肌梗死风险增加相关(HR 1.2, 95%CI 1.1-1.3),绝对风险增加0.03%/年(95%CI 0.01-0.04%),NNT=3846(95%CI 2564-7692)。
  • 口服雌二醇>1 mg/天使用超过1年与缺血性卒中风险增加相关(HR 1.8, 95%CI 1.4-2.2,使用>5年 vs 未使用)和心肌梗死风险增加相关(HR 1.8, 95%CI 1.4-2.4,使用>5年 vs 未使用),风险随治疗时间延长而增加。
  • 经皮治疗与未使用相比未增加血栓风险,但经皮联合周期性治疗与心肌梗死风险增加相关(HR 2.1, 95%CI 1.1-4.1)。

证据类型、等级与局限

  • 证据类型:观察性研究(巢式病例对照研究);局限:观察性设计不能完全排除残余混杂,原文未提供证据等级。

对床旁实践的改变

  • 对于有血栓风险的绝经女性,口服绝经激素治疗应权衡血栓风险,经皮治疗可能风险较低,但经皮联合周期性治疗仍需警惕心肌梗死风险。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate associations between current use of menopausal hormone therapy and development of venous thromboembolism, ischaemic stroke, and myocardial infarction.

DESIGN: Nationwide nested case-control study.

SETTING: National Danish health registries.

PARTICIPANTS: 9807 women with venous thromboembolism, 18 460 women with ischaemic stroke, and 11 974 women with myocardial infarction were identified in a cohort of women of 50-69 years living in Denmark between 2003 and 2021 without a medical history of venous thrombosis, arterial thrombosis, cancer, liver disease, thrombophilia, oophorectomy, infertility treatment, endometriosis, or polyendocrine metabolic ovarian syndrome (PMOS, previously known as polycystic ovary syndrome). Cases were matched by birth year to a total of 49 035, 92 300, and 59 870 women without thrombotic disease, respectively.

MAIN OUTCOME MEASURES: Receiving a first time diagnosis of venous thromboembolism, ischaemic stroke, or myocardial infarction.

RESULTS: Among women who had not used menopausal hormone therapy, incidence rates of venous thromboembolism, ischaemic stroke, and myocardial infarction per 10 000 person years were 15.8, 20.3, and 13.0, respectively. Compared with no current use, current use of oral oestrogen therapy (alone or combined with progestin) was associated with increased rates of venous thromboembolism (hazard ratio 1.6, 95% CI 1.5 to 1.8), ischaemic stroke (1.3, 1.2 to 1.4), and myocardial infarction (1.2, 1.1 to 1.3). The absolute risk increase per year was 0.09% (95% confidence interval (CI) 0.08 to 0.13%) for venous thromboembolism, 0.06% (0.04 to 0.08%) for ischaemic stroke, and 0.03% (0.01 to 0.04%) for myocardial infarction, corresponding to numbers needed to harm for one year of use of 1055 (95% CI 791 to 1266), 1642 (1232 to 2463), and 3846 (2564 to 7692), respectively.Use of oral forms of oestradiol was consistently associated with increased venous thromboembolic risk compared with no current use. Oral oestradiol doses >1 mg/day used for more than one year was associated with increased risks of ischaemic stroke and myocardial infarction, with risks increasing with treatment duration (stroke hazard ratio 1.8, 95% CI 1.4 to 2.2 and myocardial infarction hazard ratio 1.8, 1.4 to 2.4 for >5 years of use compared with no current use).Transdermal therapy was not associated with increased thrombotic rates compared with no current use, with the exception of increased risk of myocardial infarction with transdermal combined cyclic therapy (hazard ratio 2.1, 95% CI 1.1 to 4.1).

CONCLUSIONS: Compared with no current use of any hormone therapy, oral menopausal hormone therapy was associated with increased venous thromboembolic risk regardless of dosage and treatment duration, while prolonged use of high dose oral oestradiol (>1 mg/day) showed elevated risks of ischaemic stroke and myocardial infarction. No increased thrombotic risks were observed with transdermal therapy.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Berggreen J, Pourhadi N, Wood-Kurland H, et al. Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study. BMJ. 2026. PMID: 42778212. doi:10.1136/bmj-2026-100688

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。